Actuate Therapeutics files S-1 for 50 million share offering on NasdaqOct 6FinancingActuate Therapeutics Inc.
Actuate registers Phase 1/2 trial of oral elraglusib in advanced solid tumorsJul 20Trial updateActuate Therapeutics Inc.elraglusib